Derazantinib
Derazantinib (ARQ-087) is an orally bioavailable, ATP-competitive inhibitor targeting fibroblast growth factor receptors (FGFRs) with low nanomolar potency. It is used in research to investigate FGFR-driven pathologies, demonstrating activity in both in vitro assays and in vivo tumor models.
Product Specifications
CAS Number
1234356-69-4
Product Name Alternative
ARQ 087, ARQ087, ARQ-087, Derazantinib, inhibit, Inhibitor, Fibroblast growth factor receptor, FGFR, FGFR1, FGFR2, FGFR3
Field of Research
Cardiovascular Research, Signal Transduction
Purity
99.71% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.04 mM) ; DMSO:98 mg/mL (209.15 mM)
Smiles
COCCNCCc1cccc (Nc2ncc3C[C@@H] (c4ccccc4F) c4ccccc4-c3n2) c1
Molecular Formula
C29H29FN4O
Molecular Weight
468.57
Storage Conditions
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-5HT1A Receptor/HTR1A Antibody Picoband® (Biotine Conjugate)
SIM2 CRISPRa sgRNA lentivector (set of three targets)(Mouse)
4-trifluoro-4-phenyl-1,3,2-Oxathiazolylium-5-olate
SARS, Spike Protein (CT) (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (AP) discontinued
